Market Place
Sourcing Support
Oncternal Announces Updated Data For ONCT-534 In Prostate Cancer
22 Oct 2024 //
GLOBENEWSWIRE
Oncternal Therapeutics Terminates Clinical Studies, Explores Alternatives
12 Sep 2024 //
GLOBENEWSWIRE
Oncternal Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Oncternal Therapeutics To Report Q2 2024 Results And Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
11 Jul 2024 //
GLOBENEWSWIRE
Oncternal Completes Enrollment Initiates Dosing For ONCT-534 In CRPC
30 May 2024 //
GLOBENEWSWIRE
Oncternal Q1 2024 Results And Business Update
09 May 2024 //
GLOBENEWSWIRE
Oncternal Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Oncternal: Inducement Award Under Nasdaq 5635(c)(4)
01 May 2024 //
GLOBENEWSWIRE
Oncternal Doses First Patient In ONCT-534 Prostate Cancer Study
18 Apr 2024 //
GLOBENEWSWIRE
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader
15 Mar 2024 //
GLOBENEWSWIRE
Oncternal Announces Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Oncternal to Report Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Conference
06 Feb 2024 //
GLOBENEWSWIRE
Oncternal Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2024 //
GLOBENEWSWIRE
Oncternal Enrolls Patients into Phase 1/2 Study of ONCT-534
08 Jan 2024 //
GLOBENEWSWIRE
Oncternal Therapeutics Announces Reverse Stock Split
04 Jan 2024 //
GLOBENEWSWIRE
Oncternal Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
02 Jan 2024 //
GLOBENEWSWIRE
Oncternal reports patient death in CAR-T dose-escalation study
28 Dec 2023 //
FIERCE BIOTECH
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808
26 Dec 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Oncternal to Report Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534
26 Oct 2023 //
GLOBENEWSWIRE
Oncternal Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board
25 Oct 2023 //
GLOBENEWSWIRE
Oncternal Announces First Patient Dosed in Phase 1/2 Study of ONCT-534
05 Oct 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
07 Sep 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534
03 Aug 2023 //
GLOBENEWSWIRE
Oncternal to Report Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule
30 Jun 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1
06 Jun 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics to Participate at 2023 Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Provides Business Update and Announces 1Q 2023 FYR
04 May 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics to Provide Business Update and Report 1Q 2023 FYR
27 Apr 2023 //
GLOBENEWSWIRE
Oncternal Participating in Oppenheimer & Co. Virtual Fireside Chat
13 Apr 2023 //
GLOBENEWSWIRE
Facing a crowded market for BTK inhibitors, Oncternal bows out
04 Apr 2023 //
FIERCE BIOTECH
Oncternal Announces Preservation Extends Cash Runway into 2025
03 Apr 2023 //
GLOBENEWSWIRE
Oncternal Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
27 Mar 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Announces Q4 and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
Oncternal Therapeutics Report Fourth Quarter & Full Year 2022 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
Oncternal Reports Granting of Inducement Award Under Nasdaq Listing Rule
01 Mar 2023 //
GLOBENEWSWIRE
Oncternal Reports Granting of Inducement Award Under Nasdaq Listing 5635(c)(4)
01 Feb 2023 //
GLOBENEWSWIRE
Oncternal Announces the Appointment of Jill DeSimone to the Board of Directors
04 Jan 2023 //
GLOBENEWSWIRE
Oncternal Reports Granting of Inducement Award Under Nasdaq Listing Rule
03 Jan 2023 //
GLOBENEWSWIRE
Oncternal Presents Data for Zilovertamab in Combination with Ibrutinib at ASH
10 Dec 2022 //
GLOBENEWSWIRE
Oncternal Reports Granting of Inducement Award Under Nasdaq Listing Rule
01 Dec 2022 //
GLOBENEWSWIRE
Oncternal Reports Granting of Inducement Award Under Nasdaq Listing Rule
14 Nov 2022 //
GLOBENEWSWIRE
Oncternal Therapeutics to Present Updated Interim Ph 1/2 Data for Zilovertamab
03 Nov 2022 //
GLOBENEWSWIRE
Oncternal Therapeutics Provides Business Update and Announces 3Q FYR
03 Nov 2022 //
GLOBENEWSWIRE
Oncternal to Provide Business Update and Report Q3 2022 Financial Results
27 Oct 2022 //
GLOBENEWSWIRE
Oncternal Receives IND Clearance for ONCT-808, its autologous CAR T Product
03 Oct 2022 //
GLOBENEWSWIRE
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing
03 Oct 2022 //
GLOBENEWSWIRE
FDA clears Oncternal to proceed with dose escalation study
03 Oct 2022 //
SEEKINGALPHA
Oncternal Therapeutics Initiates Global Registrational Phase 3 of Zilovertamab
27 Sep 2022 //
GLOBENEWSWIRE
Oncternal to Participate in the Cantor Oncology, Hematology & HemeOnc
23 Sep 2022 //
GLOBENEWSWIRE
Oncternal Tx Provides Business Update and Announces Q2 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Oncternal Therapeutics to Report Second Quarter 2022 Financial Results
02 Aug 2022 //
GLOBENEWSWIRE
AbbVie pens Imbruvica pact to support pivotal Oncternal trial
16 Jul 2022 //
FIERCEBIOTECH
Oncternal Tx Announces Trial Collaboration to Advance Zilovertamab PIII Study
14 Jul 2022 //
GLOBENEWSWIRE
Oncternal Presents Plans for its PIII Study of Zilovertamab + Ibrutinib
10 Jun 2022 //
GLOBENEWSWIRE
